The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...

A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to ...

Tozorakimab highly promising as biologic therapy in replicate phase III trials ...

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...

AstraZeneca’s experimental COPD drug has significantly reduced flare-ups in two late-stage trials, making FDA approval in ...

An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market ...

Despite recent treatment advances in chronic obstructive pulmonary disease (COPD), physicians continue to report substantial unmet need, particularly among patients with severe disease and a high risk ...

Many patients with chronic obstructive pulmonary disease (COPD) have exacerbations despite receiving standard-of-care inhaled ...

A small trial found that laughter therapy and pursed-lip breathing reduced reported breathlessness in people with COPD.

The focus of this latest data presentation was the drug’s efficacy in reducing moderate and severe exacerbations among COPD ...

Dual bronchodilation with umeclidinium/vilanterol improved exercise cardiac function in patients with COPD, hyperinflation, ...

“Long-Term Smoking Cessation Cuts Depression Risk by 60% in Patients with Severe COPD” ...